BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 18467257)

  • 1. Occurrence of autoimmunity in a long-term survivor with metastatic colon carcinoma treated with a new chemo-immunotherapy regimen.
    Correale P; Fioravanti A; Bertoldi I; Montagnani F; Miracco C; Francini G
    J Chemother; 2008 Apr; 20(2):278-81. PubMed ID: 18467257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients.
    Correale P; Cusi MG; Tsang KY; Del Vecchio MT; Marsili S; Placa ML; Intrivici C; Aquino A; Micheli L; Nencini C; Ferrari F; Giorgi G; Bonmassar E; Francini G
    J Clin Oncol; 2005 Dec; 23(35):8950-8. PubMed ID: 16061910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine + FOLFOX followed by subcutaneous granulocyte macrophage colony-stimulating factor and aldesleukin (GOLFIG-1 Trial).
    Correale P; Tagliaferri P; Fioravanti A; Del Vecchio MT; Remondo C; Montagnani F; Rotundo MS; Ginanneschi C; Martellucci I; Francini E; Cusi MG; Tassone P; Francini G
    Clin Cancer Res; 2008 Jul; 14(13):4192-9. PubMed ID: 18593999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy.
    Correale P; Rotundo MS; Del Vecchio MT; Remondo C; Migali C; Ginanneschi C; Tsang KY; Licchetta A; Mannucci S; Loiacono L; Tassone P; Francini G; Tagliaferri P
    J Immunother; 2010 May; 33(4):435-41. PubMed ID: 20386463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase III trial.
    Correale P; Botta C; Rotundo MS; Guglielmo A; Conca R; Licchetta A; Pastina P; Bestoso E; Ciliberto D; Cusi MG; Fioravanti A; Guidelli GM; Bianco MT; Misso G; Martino E; Caraglia M; Tassone P; Mini E; Mantovani G; Ridolfi R; Pirtoli L; Tagliaferri P
    J Immunother; 2014 Jan; 37(1):26-35. PubMed ID: 24316553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Occurrence of Sjögren syndrome in a long-term survivor patient with metastatic colon carcinoma treated with GOLFIG regimen.
    Tenti S; Correale P; Conca R; Pastina P; Fioravanti A
    J Chemother; 2012 Aug; 24(4):245-6. PubMed ID: 23040694
    [No Abstract]   [Full Text] [Related]  

  • 7. Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro.
    Correale P; Cusi MG; Del Vecchio MT; Aquino A; Prete SP; Tsang KY; Micheli L; Nencini C; La Placa M; Montagnani F; Terrosi C; Caraglia M; Formica V; Giorgi G; Bonmassar E; Francini G
    J Immunol; 2005 Jul; 175(2):820-8. PubMed ID: 16002679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable/metastatic biliary tract cancer.
    Hwang IG; Jang JS; Oh SY; Rho MH; Lee S; Park YS; Park JO; Nam EM; Lee HR; Jun HJ; Chi KC
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):757-62. PubMed ID: 25677446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaliplatin and fixed-rate infusional gemcitabine in the second-line treatment of patients with metastatic colon cancer: final results of a Phase II trial prematurely closed as a result of poor accrual.
    Lopes G; Quesada J; Ahn E; Flores A; Ribeiro A; Rocha-Lima CM
    Clin Colorectal Cancer; 2007 Sep; 6(9):641-5. PubMed ID: 17945036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot study of paclitaxel combined with gemcitabine followed by interleukin-2 and granulocyte macrophage colony-stimulating factor for patients with metastatic melanoma.
    Peng RQ; Ding Y; Zhang X; Liao Y; Zheng LM; Zhang XS
    Cancer Biol Ther; 2012 Dec; 13(14):1443-8. PubMed ID: 22954698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma.
    Correale P; Messinese S; Caraglia M; Marsili S; Piccolomini A; Petrioli R; Ceciarini F; Micheli L; Nencini C; Neri A; Vuolo G; Guarnieri A; Abbruzzese A; Prete SD; Giorgi G; Francini G
    Br J Cancer; 2004 May; 90(9):1710-4. PubMed ID: 15150625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should capecitabine replace infusional fluorouracil and leucovorin when combined with oxaliplatin in metastatic colorectal cancer?
    Mayer RJ
    J Clin Oncol; 2007 Sep; 25(27):4165-7. PubMed ID: 17709796
    [No Abstract]   [Full Text] [Related]  

  • 13. PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy.
    Gill S; Ko YJ; Cripps C; Beaudoin A; Dhesy-Thind S; Zulfiqar M; Zalewski P; Do T; Cano P; Lam WYH; Dowden S; Grassin H; Stewart J; Moore M
    J Clin Oncol; 2016 Nov; 34(32):3914-3920. PubMed ID: 27621395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas.
    Olszewski AJ; Grossbard ML; Chung MS; Chalasani SB; Malamud S; Mirzoyev T; Kozuch PS
    J Gastrointest Cancer; 2013 Jun; 44(2):182-9. PubMed ID: 23208490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of 5-fluorouracil/leucovorin/gemcitabine/cisplatin as second-line treatment in patients with metastatic or recurrent colorectal carcinoma: a cancer therapeutics research group study.
    Chang AY; Lopes G; Hsin KW; Lim R; Fong FK; Wong J
    Clin Colorectal Cancer; 2007 Sep; 6(9):646-51. PubMed ID: 17945037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biweekly triple combination chemotherapy with gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil (GOLF) is a safe and active treatment for patients with inoperable pancreatic cancer.
    Correale P; Montagnani F; Miano S; Sciandivasci A; Pascucci A; Petrioli R; Testi W; Tanzini G; Francini G
    J Chemother; 2008 Feb; 20(1):119-25. PubMed ID: 18343754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
    Tsavaris N; Kosmas C; Skopelitis H; Gouveris P; Kopterides P; Loukeris D; Sigala F; Zorbala-Sypsa A; Felekouras E; Papalambros E
    Invest New Drugs; 2005 Aug; 23(4):369-75. PubMed ID: 16012797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer.
    Ch'ang HJ; Wang CC; Cheng AL; Hsu C; Lu YS; Chang MC; Lin JT; Wang HP; Shiah HS; Liu TW; Chang JY; Whang-Peng J; Chen LT
    J Gastroenterol Hepatol; 2006 May; 21(5):874-9. PubMed ID: 16704539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients.
    O'Shaughnessy JA; Denicoff AM; Venzon DJ; Danforth D; Pierce LJ; Frame JN; Bastian A; Ghosh B; Goldspiel B; Miller L
    Ann Oncol; 1994 Oct; 5(8):709-16. PubMed ID: 7826903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.